Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
Part of paid clinical trials in Milwaukee, Wisconsin.
- Sponsor
- Medical College of Wisconsin
- Study ID
- NCT06228599
- Status
- Recruiting
Conditions
- Pancreas Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Treatment Plan — OTHERA matched treatment regimen will be administered for approximately 12 weeks based on recommendations made by the MTB.
Study Details
This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.
Key Dates
- Start date
- Feb 29, 2024
- Status verified
- Apr 2026
- Primary completion
- Jan 31, 2029
- Completion
- Jan 31, 2029
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Molecular Tumor Board (MTB)-recommended matched therapyThe MTB, a multidisciplinary group composed of medical oncologists (including those with expertise in precision oncology), surgical oncologists, and a pathologist, convenes periodically to discuss and recommend an individualized treatment plan that targets specific molecular alterations (e.g., genomic mutations) found in the patient's cancer while considering patient clinical and laboratory factors.
Primary Outcome Measure
Disease-free Survival [ Time Frame: Six months ]
Central Contacts
- Medical College of Wisconsin Cancer Center Clinical Trials Office866-680-0505
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Mandana Kamgar, MD 414-805-4600 |
Find similar trials in Milwaukee, WI
Related Studies
- Promoting CT Engagement for Pancreatic Cancer With AppRecruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple MyelomaPHASE1 · Recruiting · Nammi Therapeutics Inc · Los Angeles, California
- Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- The Cancer of the Pancreas Screening-5 CAPS5)StudyPHASE3 · Recruiting · Johns Hopkins University · New Haven, Connecticut